Table 2.
Impact of baseline patient characteristics on the incidence of late urinary symptom flare 2 years post-SBRT.
| Factors | p-Value |
|---|---|
| Age | 0.007*† |
| Race | 0.505 |
| D’Amico risk groups | 0.381 |
| Gleason score (6, 7, ≥8) | 0.453 |
| T-stage (T1c, palpable) | 0.865 |
| Prostate volume | 0.820 |
| PSA | 0.299 |
| Testosterone level | 0.111 |
| Initial AUA | 0.080 |
| α1A antagonist usage | 0.975 |
| Initial EPIC urinary domain | 0.166 |
| Partner status | 0.812 |
| Work status | 0.599 |
| Charlson comorbidity index | 0.794 |
| Procedure for BPH | 0.212 |
| Androgen deprivation therapy | 0.282 |
*Significant in multivariate analysis; †significant in univariate analysis.
PSA, prostate-specific antigen; AUA, American Urological Association urinary symptom score; EPIC, expanded prostate cancer index composite; BPH, benign prostate hypertrophy.